ArticlePloS one2016
Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03351959 (Complete Pathologic Response Rectal Cancers EYSAC.1 Study), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Complete Pathologic Response Rectal Cancers EYSAC.1 Study
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- MetaNorm: incorporating meta-analytic priors into normalization of NanoString nCounter data.Bioinformatics (Oxford, England) · 2024Pooled it
- Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer.Cell reports. Medicine · 2024Article
- Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care.The Journal of molecular diagnostics : JMD · 2024Article
- Precision diagnostics in transplanted organs using microarray-assessed gene expression: concepts and technical methods of the Molecular Microscope® Diagnostic System (MMDx).Clinical science (London, England : 1979) · 2024Review
- Article
- A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.Blood advances · 2022Article
- Changes in the brain transcriptome after DNA Aβ42 trimer immunization in a 3xTg-AD mouse model.Neurobiology of disease · 2021Article
- A random forest based biomarker discovery and power analysis framework for diagnostics research.BMC medical genomics · 2020Article
- mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population.Gynecologic oncology · 2020Article
- Multi-gene technical assessment of qPCR and NanoString n-Counter analysis platforms in cynomolgus monkey cardiac allograft recipients.Cellular immunology · 2020Article
- Identification of Monotonically Differentially Expressed Genes across Pathologic Stages for Cancers.Journal of oncology · 2020Article
- Detection of gene mutations in gastric cancer tissues using a commercial sequencing panel.Molecular and clinical oncology · 2019Article
- Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.BMC genomics · 2019Article
- Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip.Disease markers · 2019Article
- Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.Blood advances · 2018Article
- Transcriptome profiling analysis reveals biomarkers in colon cancer samples of various differentiation.Oncology letters · 2018Article
- Targeted Transcriptional Profiling of Kidney Transplant Biopsies.Kidney international reports · 2018Article
- Gene Expression Detection Assay for Cancer Clinical Use.Journal of Cancer · 2018Review
- The heterogeneous landscape of ALK negative ALCL.Oncotarget · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The prognosis of colorectal cancer (CRC) stage II and III patients remains a challenge due to the difficulties of finding robust biomarkers suitable for testing clinical samples. The majority of published gene signatures of CRC have been generated on fresh frozen colorectal tissues. Because collection of frozen tissue is not practical for routine surgical pathology practice, a clinical test that improves prognostic capabilities beyond standard pathological staging of colon cancer will need to be designed for formalin-fixed paraffin-embedded (FFPE) tissues. The NanoString nCounter® platform is a gene expression analysis tool developed for use with FFPE-derived samples. We designed a custom nCounter® codeset based on elements from multiple published fresh frozen tissue microarray-based prognostic gene signatures for colon cancer, and we used this platform to systematically compare gene expression data from FFPE with matched microarray array data from frozen tissues. Our results show moderate correlation of gene expression between two platforms and discovery of a small subset of genes as candidate biomarkers for colon cancer prognosis that are detectable and quantifiable in FFPE tissue sections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.